fbpx

Larvol Omni

Discover the next generation of KOL and drug tracking with Larvol Omni
Request A Demo

Stay ahead with comprehensive updates on KOL and drug activity.
Omni includes publications, clinical trial involvement, social media, and upcoming event attendance.

Keep Up-to-Date

larvol-thought-leader

Clyde W. Yancy, MD

Northwestern University Feinberg School of Medicine, Chicago, IL, US

llllllllll Routinely reported ejection fraction and mortality in clinical practice

(PracticeUpdate), 08/13/2019

Finally, given the consistent shortcomings observed in the best application of guideline-directed medical therapy (GDMT), we should be hesitant to halt our calibration of risk after the first assessment of ventricular function. Rather, we should be diligent in repeating the measurement of ejection fraction as optimization of heart failure therapy ensues.
Online Posting

llllllllll At Issue: Lancet initiative sparks discussion on diversity in cardiology

(Healio), 08/12/2019

Sometimes I see adequately diverse representation on the podium at cardiology meetings I attend in some sessions, but often I leave feeling there is not enough. But here’s the great thing: Our next ACC president is a woman, Athena Poppas, MD, who will assume the presidency in March 2020….This discussion instigated by the Lancet group merits further exploration.
Media Post

Heart Failure Holiday Symposium

012/05/2019, Chicago, IL, USA

“We will celebrate our 15th Annual Northwestern Holiday Heart Failure Symposium, by including an evening of lectures and discussions focused on career paths in heart failure, to be held Thursday, December 5th 2019 at The Radisson Blu Aqua Hotel from 6:00-8:30pm.”
CME

THI Grand Rounds

03/06/2020, Houston, TX, USA

Texas Heart Institute is accredited by the Accreditation Council or Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Grand Rounds

TCT 2019 Transcatheter Cardiovascular Therapeutics Annual Conference

09/25/2019 – 09/29/2019, San Francisco, CA
5 Abstracts

HFSA 2019 23rd Annual Scientific Meeting of Heart Failure Society of America

09/13/2019 – 09/16/2019, Philadelphia, PA
14 Abstracts

ASS-ASNC 2019 24th Annual Scientific Session of the American Society of Nuclear Cardiology

09/12/2019 – 09/15/2019, Chicago, IL
2 Abstracts

PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized with Heart Failure

PubMed
Clinical

Representatives of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF

PubMed
Natrecor

A new and potentially important phenotype of heart failure emerges

Clyde Yancy, MD, @NMHheartdoc

“A new and potentially important phenotype of heart failure emerges; an evolving database suggests that HF with midrange EF is associated with better outcomes. No yet identified therapies. Continue GDMT. Need to discover pathways of recovery.”
Tweet

Leading the way for a bold future

Clyde Yancy, MD, @NMHheartdoc

“Leading the way for a bold future; Masters level training in Artificial Intelligence- new language, new tool and new opportunities. Looking forward to seeing the best of the best apply and work with @NMCardioVasc @JamesDThomasMD1 @NorthwesternMed @NUFeinbergMed”
Tweet

IMPROVE-HF: IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting

P=N/A

Completed

AC6 Gene Transfer for CHF

P1/2

Completed

Omni Content

Key Features

Push Notifications

Bookmark Content

KOL Analytics

Take Notes

Sunshine Data

Contact Info

Why Track KOLs?

IMPROVE UNDERSTANDING

We know how valuable the opinions of KOLs are. Monitoring KOL activity allows for a better understanding of how the physician community receives your messages and lets you identify concerns and education opportunities. Never miss an opportunity to engage.

DISCOVER ENGAGEMENT OPPORTUNITIES

Tracking KOLs ensures that your products are included in relevant discussions. Knowing where a KOL is going to be – which conferences, symposiums, and CME events they’ll be attending or presenting at – allows for crucial opportunities to engage with a KOL and the other physicians who follow them. Our customers explain how valuable it is to see that a KOL is publicly discussing mechanisms of action that they’re working with and creates an opportunity to reach out and establish a key relationship.

TRACKING vs MAPPING

Mapping is the process of identifying thought leaders / KOLs that are influential in your area and their relationships. Tracking comes after mapping and involves monitoring the ongoing activity (publications, opinions, and events) of specific KOLs to better understand the evolution of their positioning. Tracking also ensures that you are up-to-date with the perspectives of your KOLs and that you can identify opportunities to engage with them.

Our Complete KOL and Drug Monitoring Solution Includes

News

Publications, trial updates, news, media mentions – any news item that isn’t an event or a tweet.

Events

Calendar listing of upcoming conferences, symposiums, lectures, CME and other events that a KOL is attending or speaking at.

Social Media

Twitter provides a direct line to your key influencers’ reactions. You can find tweets authored by the KOL as well as mentions of the KOL by others.

Clinical Trials

Updates on the latest clinical trials associated with your KOLs, covering both clinicaltrials.gov and EudraCT. Includes changes such as enrollment status, new data, discontinuations and more.

Request A Demo

Enter your information to be contacted by our sales team about Larvol Omni,

to schedule a demo, or subscribe.

By signing up for a free report or trial, you agree to our Privacy Policy
Yes, I would like to subscribe to updates from Larvol